- 3TC
lamivudine
- BIC
bictegravir
- AE
adverse event
- ABC
abacavir
- ART
antiretroviral therapy
- ARV
antiretroviral
- CI
confidence interval
- CTAC
Canadian Treatment Action Council
- DB
double-blind
- DHHS
US Department of Health and Human Services
- DTG
dolutegravir
- DOR
doravirine
- DRV
darunavir
- DRV/r
ritonavir-boosted darunavir
- DSG
delayed switch group
- EFV
efavirenz
- EVG
elvitegravir
- EQ-5D-5L
EuroQol 5-Dimensions 5-Levels questionnaire
- FAS
full-analysis set
- FDC
fixed-dose combination
- FTC
emtricitabine
- HDL
high-density lipoprotein cholesterol
- IDC
indirect comparison
- InSTI
integrase strand transfer inhibitor
- ISG
immediate switch group
- IVRS/IVWS
interactive voice/Web response system
- LDL
low-density lipoprotein cholesterol
- MCID
minimal clinically important difference
- NIM
noninferiority margin
- NMA
network meta-analysis
- NNRTI
non-nucleoside reverse transcriptase inhibitor
- NRTI
nucleoside reverse transcriptase inhibitor
- OL
open-label
- PDVF
protocol-defined virologic failure
- PI
protease inhibitor
- PP
per-protocol
- RCT
randomized controlled trial
- RAM
resistance-associated mutation
- RNA
ribonucleic acid
- SAE
serious adverse event
- SD
standard deviation
- STR
single-tablet regimen
- TAF
tenofovir alafenamide
- TDF
tenofovir disoproxil fumarate
- ULN
upper limit of normal
- WDAE
withdrawal due to adverse event
Publication Details
Copyright
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
Clinical Review Report: Doravirine (Pifeltro): (Merck Canada Inc.): Indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. Abbreviations.